Lumito Arrow right Arrow right

Lumito’s imaging technology, based on Up-Converting Nano Particles (“UCNP”), can create products for imaging of tissues in living organisms (in vivo) as well as of tissue samples in a laboratory environment (in vitro). Lumito’s development focus is now on in vitro. The method provides a higher image quality than current technologies, with high contrast and without background signal. The pictures only show what we are looking for. No other tissue or information is shown.

Higher image quality, safer diagnoses, and faster analysis response

The technology has higher image quality with high contrast and level of detail, compared to traditional immunohistochemistry. It also facilitates computer analysis and provides the opportunity to make staining’s with both Lumito´s and traditional reagents in the same tissue. Thus, several tests can be performed in one single tissue. There is also potential to connect decision support such as AI.

The technology has several potential applications, but Lumito has, as the first step, chosen to develop an instrument and reagents for digital pathology, i.e. digitised tissue diagnostics where the analysis can be computer-supported and remote.

The requirements for individualised treatments and disease prognoses are growing fast, as they reduce suffering for patients and lower the cost of healthcare. The need for prompt and accurate diagnosis of diseases/tumours not only means high technical requirements for modern analytical equipment, but it should also be adapted to an altered workflow with fewer manual elements.

Digital pathology

Digital pathology is used in healthcare to save costs and shorten test times. The pathology of today is largely performed in the same way it has been for decades, by staining with Haematoxylin and Eosin in thin tissue sections. Even though each section is studied by a pathologist, many incorrect diagnoses occur. Today’s immunohistochemistry is very limited because it was developed primarily for traditional pathology, where microscopic samples are studied; it must be visible light because the human eye examines the sample and fluorescence imaging cannot be used. Lumito’s technology is much better suited to computer analysis than traditional immunohistochemistry because the image quality is so high; the diagnoses become safer and responses can be given faster.Although the digitisation of pathology provides a greater degree of freedom, many problems persist. With Lumito’s technique, a large tissue sample can be studied quickly, and just the areas containing the tissue being looked for can be depicted with higher resolution. This is crucial for speeding up the digitisation process itself.

A vision for the future for surgeons and pathologists is being able to diagnose tissue already on the operating table, or even better, before surgery. Lumito’s technology has the potential to do this.


A patented technology

Lumito has patented its technology with three worldwide patent families, that cover the creation of high-quality imaging of tissue, for instance in tumours, with UCNP:s as markers.

One patent family protects the use of Upconverting Nanoparticles (UCNP:s) for imaging in propagating material, such as human tissue. This family has patents approved in key regions worldwide and provides broad protection, even beyond medical use.

The second patent family, also with patents approved in key regions, describes the use of light pulses to improve technology efficiency and provide shorter imaging times.

The third patent family protects the use of UCNP:s in tissue diagnostics, the specific application area in which Lumito intends to launch its first product.